Non-immunosuppressive treatment for IgA nephropathy
Sharon Reid1, Peggy M Cawthon, Jonathan C Craig
1Sydney School of Public Health, University of Sydney, Edward Ford Building (A27), Room 301C, Sydney, NSW, Australia, 2006.
The Cochrane Database of Systematic Reviews
|March 18, 2011
Summary
Antihypertensive agents, particularly renin-angiotensin system inhibitors, show potential benefits for IgA nephropathy (IgAN) by reducing proteinuria. However, more robust trials are needed to confirm efficacy and safety for IgAN patients.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- IgA nephropathy (IgAN) is a leading cause of end-stage kidney disease (ESKD), affecting 30-40% of patients within 20 years.
- Current treatments often involve immunosuppressive agents with significant long-term risks.
- Non-immunosuppressive options require systematic review for efficacy and safety.
Purpose of the Study:
- To evaluate the benefits and harms of non-immunosuppressive treatments for IgA nephropathy (IgAN) in adult and pediatric populations.
- To synthesize evidence from randomized controlled trials (RCTs) on alternative IgAN therapies.
- To identify knowledge gaps in the management of IgAN.
Main Methods:
- Comprehensive literature search of Cochrane Renal Group's specialized register, CENTRAL, MEDLINE, and EMBASE up to July 2010.
- Inclusion of randomized controlled trials (RCTs) of non-immunosuppressive agents in biopsy-proven IgAN patients.
- Independent data extraction and quality assessment by two authors, with meta-analysis using random-effects models.
Main Results:
- Antihypertensive agents, primarily ACE inhibitors (ACEi) and ARBs, emerged as the most beneficial non-immunosuppressive intervention for IgAN.
- These agents demonstrated benefits mainly through proteinuria reduction, a surrogate outcome.
- Evidence for other non-immunosuppressive therapies was insufficient to demonstrate efficacy, with no significant harm or benefit established.
Conclusions:
- IgAN management requires more adequately powered RCTs to guide clinical practice.
- Further research is needed to clarify the benefits and risks of ACEi/ARB therapy in IgAN, identifying patient subgroups most likely to benefit.
- Exploration of other non-immunosuppressive therapies is warranted due to the lack of demonstrated harm.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...